Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion
Launched by IMPERIAL COLLEGE LONDON · Oct 16, 2015
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a specific type of genetic material called circulating tumor DNA (ctDNA) in patients with colorectal cancer, specifically looking at how it relates to certain imaging features of extramural venous invasion (EMVI). The goal is to better understand how ctDNA can provide information about the cancer and its behavior. This study does not involve randomization or treatment; instead, it focuses on collecting blood samples from patients who have been diagnosed with colorectal adenocarcinoma but do not have cancer that has spread to other parts of the body.
To join the study, patients must be at least 16 years old, have a confirmed diagnosis of colorectal cancer, and be eligible for surgery aimed at curing the cancer. They should not have any signs of cancer spread on their scans and must have completed a specific imaging test in the six weeks before their surgery. Participants will have two blood samples taken: one before surgery and another either during or shortly after the surgery. After that, they will be followed up annually for up to three years. This trial is currently looking for participants, and anyone interested should speak with their healthcare provider for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Have a biopsy-confirmed colorectal adenocarcinoma
- • 2. Is eligible for curative surgery
- • 3. Has no metastatic disease on CT scan
- • 4. Has completed pre-operative staging scan within six weeks prior to surgery
- • 5. Have provided written informed consent to participate in the study
- • 6. Be aged 16 years or over
- Exclusion Criteria:
- • 1. Have metastatic disease (including resectable liver metastases)
- • 2. Have a synchronous second malignancy
- • 3. Are contraindicated for any imaging able to determine EMVI status
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Margate, Kent, United Kingdom
Sutton, Surrey, United Kingdom
Hammersmith, London, United Kingdom
Patients applied
Trial Officials
Gina Brown, MD
Principal Investigator
Imperial College London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials